This document provides information about a patient's history and treatment plan. It summarizes that the patient is a 25-year-old male who has been experiencing sexual attraction towards children for 9 years, concerns about penis size for 8 years, low mood for 8 years, and headaches for 2 years. He has been treated by multiple doctors with various medications without significant improvement in his symptoms. The diagnosis is hypochondriacal disorder, pedophilia, dysthymia, depressive episode, tension headaches and probable migraines. The treatment plan is to continue SSRI medication and topiramate, and add cognitive behavioral therapy and psychoeducation for the patient and his family.
This session will discuss the use of telemedicine by the University of Virginia Department of Psychiatry to provide clinical care to primary care agency patients in Southwest Virginia. Consultation and collaborative models of care will be presented, along with a discussion of the strengths and challenges of this technology for treatment of mental health problems. Since 2007, UVA and Clinch River Health Services have contracted to provide psychiatric evaluation and medication management for Dungannon patients. The psychiatric and primary care providers will present a case study illustrating the application of the collaborative model, and discuss the emerging questions related to expansion of this important access to care for rural Virginians.
Niemann-Pick Disease Type A (NPD-A) is a genetic metabolic disorder. It is a rare disease which occurs largely in certain ethnic groups. Due to its rarity, it is difficult to diagnosis and considered untreatable by Western medicine. Based on the theory, diagnosis and therapeutic methods of Traditional Chinese Medicine (TCM) Pediatrics, the author has implemented a regular course of herbs, acupuncture and an over 2000 year old, Chinese baby Tuina (massage) treatments for the NPA child. This treatment plan is designed to stimulate immunity and detoxification, as well as to improve the immune, neurological and digestive systems.
Subtitle: The Moral Imperative of Integrative Medicine
This presentation, two hours in length, was delivered to the A4m MMI Audience in their Frontiers of Neurology - Module 3.
The following topics are reviewed:
- ADHD, Autism, Depression, Schizophrenia
- the impact of neuroinflammation on all of these.
- confounding factors and the ways to mitigate them: Omega6/Omega 3 imbalance in the Western diet, MTHFR polymorphism, the use of elemental lithium, the presence of intestinal dysbiosis and the role of gluten/dairy IgG Food allergies.
- pharmacogenomic testing
PLEASE FOLLOW THE INSTRUCTIONS AS INDICATED BELOW1). ZERO (0) PL.docxcherry686017
PLEASE FOLLOW THE INSTRUCTIONS AS INDICATED BELOW
1). ZERO (0) PLAGIARISM
2). ATLEAST 5 REFERENCES, NO MORE THAN 5 YEARS
3). PLEASE SEE ATTACHED RUBRIC DETAILS AND RECOMMENDED COURSE WRITING TEMPLATE AND APA 7 STYLE
4). Please review and follow the grading rubric details, and include each component in the assignment as required. Also, follow the APA writing rules and style, Title page, summary, Purpose statement, Conclusion.
For your Assignment, your Instructor will assign you one of the decision tree interactive media pieces provided in the Resources. As you examine the patient case studies in this module’s Resources, consider how you might assess and treat patients presenting symptoms of neurological and musculoskeletal disorders.
To Prepare
Review the interactive media piece assigned.
Reflect on the patient’s symptoms and aspects of the disorder presented in the interactive media piece.
Consider how you might assess and treat patients presenting with the symptoms of the patient case study you were assigned.
You will be asked to make three decisions concerning the diagnosis and treatment for this patient. Reflect on potential co-morbid physical as well as patient factors that might impact the patient’s diagnosis and treatment.
Write a 1- to 2-page summary paper that addresses the following:
Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.
Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.
Alzheimer’s Disease
76-year-old Iranian Male
BACKGROUND
Mr. Akkad is a 76 year old Iranian male who is brought to your office by his eldest son for “strange behavior.” Mr. Akkad was seen by his family physician who ruled out any organic basis for Mr. Akkad’s behavior. All laboratory and diagnostic imaging tests (including CT-scan of the head) were normal.
According to his son, he has been demonstrating some strange thoughts and behaviors for the past two years, but things seem to be getting worse. Per the client’s son, the family noticed that Mr. Akkad’s personality began to change a few years ago. He began to lose interest in religious activities with the family and became more “critical” of everyone. They also noticed that things he used to take seriously had become a source of “amusement” and “ridicule.”
Over the c.
Alzheimers Diseaseo Prepare· Review the interactive me.docxjack60216
Alzheimer's Disease"
o Prepare
· Review the interactive media piece assigned by your Instructor.
· Reflect on the patient’s symptoms and aspects of the disorder presented in the interactive media piece.
· Consider how you might assess and treat patients presenting with the symptoms of the patient case study you were assigned.
· You will be asked to make three decisions concerning the diagnosis and treatment for this patient. Reflect on potential co-morbid physical as well as patient factors that might impact the patient’s diagnosis and treatment.
Write a 1- to 2-page summary paper that addresses the following:
· Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.
· Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
· What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
· Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.
Interactive media piece case study below:
BACKGROUND
Mr. Akkad is a 76 year old Iranian male who is brought to your office by his eldest son for “strange behavior.” Mr. Akkad was seen by his family physician who ruled out any organic basis for Mr. Akkad’s behavior. All laboratory and diagnostic imaging tests (including CT-scan of the head) were normal.
According to his son, he has been demonstrating some strange thoughts and behaviors for the past two years, but things seem to be getting worse. Per the client’s son, the family noticed that Mr. Akkad’s personality began to change a few years ago. He began to lose interest in religious activities with the family and became more “critical” of everyone. They also noticed that things he used to take seriously had become a source of “amusement” and “ridicule.”
Over the course of the past two years, the family has noticed that Mr. Akkad has been forgetting things. His son also reports that sometimes he has difficult “finding the right words” in a conversation and then will shift to an entirely different line of conversation.
SUBJECTIVE
During the clinical interview, Mr. Akkad is pleasant, cooperative and seems to enjoy speaking with you. You notice some confabulation during various aspects of memory testing, so you perform a Mini-Mental State Exam. Mr. Akkad scores 18 out of 30 with primary deficits in orientation, registration, attention & calculation, and recall. The score suggests moderate dementia.
MENTAL STATUS EXAM
Mr. Akkad is 76 year old Iranian male.
Multiple sclerosis case scenario study basedtasbeehalibra
Case scenario of multiple sclerosis . Disease modification drugs. Ljermitte sign. Cerebellar sign. Uthoff phenomenon . Parkinsonism neurology neurosurgery. Cerebellar signs diseasSymptoms of MS vary from person to person and depend on the location and severity of nerve fibre damage. These often include vision problems, tiredness, trouble walking and keeping balance, and numbness or weakness in the arms and legs. Symptoms can come and go or last for a long time.
The causes of MS are not known but a family history of the disease may increase the risk.
While there is no cure for MS, treatment can reduce symptoms, prevent further relapses and improve quality of life.Disease course
Most people with MS have a relapsing-remitting disease course. They experience periods of new symptoms or relapses that develop over days or weeks and usually improve partially or completely. These relapses are followed by quiet periods of disease remission that can last months or even years.
Small increases in body temperature can temporarily worsen signs and symptoms of MS. These aren't considered true disease relapses but pseudorelapses.
At least 20% to 40% of those with relapsing-remitting MS can eventually develop a steady progression of symptoms, with or without periods of remission, within 10 to 20 years from disease onset. This is known as secondary-progressive MS.
The worsening of symptoms usuallyCauses
The cause of multiple sclerosis is unknown. It's considered an immune mediated disease in which the body's immune system attacks its own tissues. In the case of MS, this immune system malfunction destroys the fatty substance that coats and protects nerve fibers in the brain and spinal cord (myelin).
Myelin can be compared to the insulation coating on electrical wires. When the protective myelin is damaged and the nerve fiber is exposed, the messages that travel along that nerve fiber may be slowed or blocked.
It isn't clear why MS develops in some people and not others. A combination of genetics and environmental factors appears to be responsible.
Risk factors
These factors may increase your risk of developing multiple sclerosis:
Age. MS can occur at any age, but onset usually occurs around 20 and 40 years of age. However, younger and older people can be affected.
Sex. Women are more than 2 to 3 times as likely as men are to have relapsing-remitting MS.
Family history. If one of your parents or siblings has had MS, you are at higher risk of developing the disease.
Certain infections. A variety of viruses have been linked to MS, including Epstein-Barr, the virus that causes infectious mononucleosis.
Race. White people, particularly those of Northern European descent, are at highest risk of developing MS. People of Asian, African or Native American descent have the lowest risk. A recent study suggests that the number of Black and Hispanic young adults with multiple sclerosis may be greater than previously thought.
Climate. MS is far more common in countries wit
GRIN-related epileptic encephalopathy can present early in life with intellectual disability, continuous spike-and-wave during sleep syndrome (CSWS), or epilepsy-aphasia spectrum phenotypes such as in Landau-Kleffner syndrome. Efficacy of IVIG treatment was recently reported in a patient with LKS related to GRIN2A mutation.
We describe our experience with IVIG therapy in 5 patients (4 males, age range 6 months-13 years) with confirmed GRIN-related epileptic encephalopathy (4 with GRIN2A mutations presenting with epilepsy-aphasia spectrum/epileptic encephalopathy with CSWS and verbal, communicative and
behavioural regression, and one patient with GRIN2D mutation who presented with early infantile developmental-epileptic encephalopathy). All patients had global developmental delay/ intellectual disability in various degrees and were resistant to anticonvulsants. None of the patients had clinical seizures as a hallmark. All patients received monthly infusion of IVIG 2 g/ kg for 6 months; 2 patients were also treated with high-dose corticosteroids. No seizures were observed during the treatment
period in any of these patients. Marked electrographical improvement was noted in 4/5 patients, with complete normalization of the EEG in 2 patients. Expressive and receptive verbal abilities, communication skills and behaviour (hyperactivity, impulsivity and attention disorders) improved. However, visuospatial perceptual/spatial abilities, as well as executive functions and attention span remained significantly impaired.
Conclusion: IVIG should be considered in the treatment of GRIN-related epileptic encephalopathy and may lead to EEG normalization. Early treatment is advocated to rescue developmental milestones and improve developmental potential. Autoimmune mechanism in GRIN-related diseases should be further investigated.
This session will discuss the use of telemedicine by the University of Virginia Department of Psychiatry to provide clinical care to primary care agency patients in Southwest Virginia. Consultation and collaborative models of care will be presented, along with a discussion of the strengths and challenges of this technology for treatment of mental health problems. Since 2007, UVA and Clinch River Health Services have contracted to provide psychiatric evaluation and medication management for Dungannon patients. The psychiatric and primary care providers will present a case study illustrating the application of the collaborative model, and discuss the emerging questions related to expansion of this important access to care for rural Virginians.
Niemann-Pick Disease Type A (NPD-A) is a genetic metabolic disorder. It is a rare disease which occurs largely in certain ethnic groups. Due to its rarity, it is difficult to diagnosis and considered untreatable by Western medicine. Based on the theory, diagnosis and therapeutic methods of Traditional Chinese Medicine (TCM) Pediatrics, the author has implemented a regular course of herbs, acupuncture and an over 2000 year old, Chinese baby Tuina (massage) treatments for the NPA child. This treatment plan is designed to stimulate immunity and detoxification, as well as to improve the immune, neurological and digestive systems.
Subtitle: The Moral Imperative of Integrative Medicine
This presentation, two hours in length, was delivered to the A4m MMI Audience in their Frontiers of Neurology - Module 3.
The following topics are reviewed:
- ADHD, Autism, Depression, Schizophrenia
- the impact of neuroinflammation on all of these.
- confounding factors and the ways to mitigate them: Omega6/Omega 3 imbalance in the Western diet, MTHFR polymorphism, the use of elemental lithium, the presence of intestinal dysbiosis and the role of gluten/dairy IgG Food allergies.
- pharmacogenomic testing
PLEASE FOLLOW THE INSTRUCTIONS AS INDICATED BELOW1). ZERO (0) PL.docxcherry686017
PLEASE FOLLOW THE INSTRUCTIONS AS INDICATED BELOW
1). ZERO (0) PLAGIARISM
2). ATLEAST 5 REFERENCES, NO MORE THAN 5 YEARS
3). PLEASE SEE ATTACHED RUBRIC DETAILS AND RECOMMENDED COURSE WRITING TEMPLATE AND APA 7 STYLE
4). Please review and follow the grading rubric details, and include each component in the assignment as required. Also, follow the APA writing rules and style, Title page, summary, Purpose statement, Conclusion.
For your Assignment, your Instructor will assign you one of the decision tree interactive media pieces provided in the Resources. As you examine the patient case studies in this module’s Resources, consider how you might assess and treat patients presenting symptoms of neurological and musculoskeletal disorders.
To Prepare
Review the interactive media piece assigned.
Reflect on the patient’s symptoms and aspects of the disorder presented in the interactive media piece.
Consider how you might assess and treat patients presenting with the symptoms of the patient case study you were assigned.
You will be asked to make three decisions concerning the diagnosis and treatment for this patient. Reflect on potential co-morbid physical as well as patient factors that might impact the patient’s diagnosis and treatment.
Write a 1- to 2-page summary paper that addresses the following:
Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.
Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.
Alzheimer’s Disease
76-year-old Iranian Male
BACKGROUND
Mr. Akkad is a 76 year old Iranian male who is brought to your office by his eldest son for “strange behavior.” Mr. Akkad was seen by his family physician who ruled out any organic basis for Mr. Akkad’s behavior. All laboratory and diagnostic imaging tests (including CT-scan of the head) were normal.
According to his son, he has been demonstrating some strange thoughts and behaviors for the past two years, but things seem to be getting worse. Per the client’s son, the family noticed that Mr. Akkad’s personality began to change a few years ago. He began to lose interest in religious activities with the family and became more “critical” of everyone. They also noticed that things he used to take seriously had become a source of “amusement” and “ridicule.”
Over the c.
Alzheimers Diseaseo Prepare· Review the interactive me.docxjack60216
Alzheimer's Disease"
o Prepare
· Review the interactive media piece assigned by your Instructor.
· Reflect on the patient’s symptoms and aspects of the disorder presented in the interactive media piece.
· Consider how you might assess and treat patients presenting with the symptoms of the patient case study you were assigned.
· You will be asked to make three decisions concerning the diagnosis and treatment for this patient. Reflect on potential co-morbid physical as well as patient factors that might impact the patient’s diagnosis and treatment.
Write a 1- to 2-page summary paper that addresses the following:
· Briefly summarize the patient case study you were assigned, including each of the three decisions you took for the patient presented.
· Based on the decisions you recommended for the patient case study, explain whether you believe the decisions provided were supported by the evidence-based literature. Be specific and provide examples. Be sure to support your response with evidence and references from outside resources.
· What were you hoping to achieve with the decisions you recommended for the patient case study you were assigned? Support your response with evidence and references from outside resources.
· Explain any difference between what you expected to achieve with each of the decisions and the results of the decision in the exercise. Describe whether they were different. Be specific and provide examples.
Interactive media piece case study below:
BACKGROUND
Mr. Akkad is a 76 year old Iranian male who is brought to your office by his eldest son for “strange behavior.” Mr. Akkad was seen by his family physician who ruled out any organic basis for Mr. Akkad’s behavior. All laboratory and diagnostic imaging tests (including CT-scan of the head) were normal.
According to his son, he has been demonstrating some strange thoughts and behaviors for the past two years, but things seem to be getting worse. Per the client’s son, the family noticed that Mr. Akkad’s personality began to change a few years ago. He began to lose interest in religious activities with the family and became more “critical” of everyone. They also noticed that things he used to take seriously had become a source of “amusement” and “ridicule.”
Over the course of the past two years, the family has noticed that Mr. Akkad has been forgetting things. His son also reports that sometimes he has difficult “finding the right words” in a conversation and then will shift to an entirely different line of conversation.
SUBJECTIVE
During the clinical interview, Mr. Akkad is pleasant, cooperative and seems to enjoy speaking with you. You notice some confabulation during various aspects of memory testing, so you perform a Mini-Mental State Exam. Mr. Akkad scores 18 out of 30 with primary deficits in orientation, registration, attention & calculation, and recall. The score suggests moderate dementia.
MENTAL STATUS EXAM
Mr. Akkad is 76 year old Iranian male.
Multiple sclerosis case scenario study basedtasbeehalibra
Case scenario of multiple sclerosis . Disease modification drugs. Ljermitte sign. Cerebellar sign. Uthoff phenomenon . Parkinsonism neurology neurosurgery. Cerebellar signs diseasSymptoms of MS vary from person to person and depend on the location and severity of nerve fibre damage. These often include vision problems, tiredness, trouble walking and keeping balance, and numbness or weakness in the arms and legs. Symptoms can come and go or last for a long time.
The causes of MS are not known but a family history of the disease may increase the risk.
While there is no cure for MS, treatment can reduce symptoms, prevent further relapses and improve quality of life.Disease course
Most people with MS have a relapsing-remitting disease course. They experience periods of new symptoms or relapses that develop over days or weeks and usually improve partially or completely. These relapses are followed by quiet periods of disease remission that can last months or even years.
Small increases in body temperature can temporarily worsen signs and symptoms of MS. These aren't considered true disease relapses but pseudorelapses.
At least 20% to 40% of those with relapsing-remitting MS can eventually develop a steady progression of symptoms, with or without periods of remission, within 10 to 20 years from disease onset. This is known as secondary-progressive MS.
The worsening of symptoms usuallyCauses
The cause of multiple sclerosis is unknown. It's considered an immune mediated disease in which the body's immune system attacks its own tissues. In the case of MS, this immune system malfunction destroys the fatty substance that coats and protects nerve fibers in the brain and spinal cord (myelin).
Myelin can be compared to the insulation coating on electrical wires. When the protective myelin is damaged and the nerve fiber is exposed, the messages that travel along that nerve fiber may be slowed or blocked.
It isn't clear why MS develops in some people and not others. A combination of genetics and environmental factors appears to be responsible.
Risk factors
These factors may increase your risk of developing multiple sclerosis:
Age. MS can occur at any age, but onset usually occurs around 20 and 40 years of age. However, younger and older people can be affected.
Sex. Women are more than 2 to 3 times as likely as men are to have relapsing-remitting MS.
Family history. If one of your parents or siblings has had MS, you are at higher risk of developing the disease.
Certain infections. A variety of viruses have been linked to MS, including Epstein-Barr, the virus that causes infectious mononucleosis.
Race. White people, particularly those of Northern European descent, are at highest risk of developing MS. People of Asian, African or Native American descent have the lowest risk. A recent study suggests that the number of Black and Hispanic young adults with multiple sclerosis may be greater than previously thought.
Climate. MS is far more common in countries wit
GRIN-related epileptic encephalopathy can present early in life with intellectual disability, continuous spike-and-wave during sleep syndrome (CSWS), or epilepsy-aphasia spectrum phenotypes such as in Landau-Kleffner syndrome. Efficacy of IVIG treatment was recently reported in a patient with LKS related to GRIN2A mutation.
We describe our experience with IVIG therapy in 5 patients (4 males, age range 6 months-13 years) with confirmed GRIN-related epileptic encephalopathy (4 with GRIN2A mutations presenting with epilepsy-aphasia spectrum/epileptic encephalopathy with CSWS and verbal, communicative and
behavioural regression, and one patient with GRIN2D mutation who presented with early infantile developmental-epileptic encephalopathy). All patients had global developmental delay/ intellectual disability in various degrees and were resistant to anticonvulsants. None of the patients had clinical seizures as a hallmark. All patients received monthly infusion of IVIG 2 g/ kg for 6 months; 2 patients were also treated with high-dose corticosteroids. No seizures were observed during the treatment
period in any of these patients. Marked electrographical improvement was noted in 4/5 patients, with complete normalization of the EEG in 2 patients. Expressive and receptive verbal abilities, communication skills and behaviour (hyperactivity, impulsivity and attention disorders) improved. However, visuospatial perceptual/spatial abilities, as well as executive functions and attention span remained significantly impaired.
Conclusion: IVIG should be considered in the treatment of GRIN-related epileptic encephalopathy and may lead to EEG normalization. Early treatment is advocated to rescue developmental milestones and improve developmental potential. Autoimmune mechanism in GRIN-related diseases should be further investigated.
Case An elderly widow who just lost her spouse. Subjective.docxcowinhelen
Case: An elderly widow who just lost her spouse.
Subjective: A patient presents to your primary care office today with chief complaint of insomnia. Patient is 75 YO with PMH of DM, HTN, and MDD. Her husband of 41 years passed away 10 months ago. Since then, she states her depression has gotten worse as well as her sleep habits. The patient has no previous history of depression prior to her husband’s death. She is awake, alert, and oriented x3. Patient normally sees PCP once or twice a year. Patient denies any suicidal ideations. Patient arrived at the office today by private vehicle. Patient currently takes the following medications:
• Metformin 500mg BID
• Januvia 100mg daily
• Losartan 100mg daily
• HCTZ 25mg daily
• Sertraline 100mg daily
Current weight: 88 kg
Current height: 64 inches
Temp: 98.6 degrees F
BP: 132/86
Insomnia is a disorder linked with difficulty in sleep quality, initiating or maintaining sleep, along with substantial distress and impairments of daytime functioning. Its prevalence ranges from 10 to 15% among the general population, with higher rates seen among females, divorced or separated individuals, those with loss of loved ones, and older people (Bollu & Kaur, 2019). Insomnia can simply be defined as a sleep disorder where the patient has trouble falling asleep or staying asleep. According to Krystal et al (2019), it is a common condition that is linked with noticeable deterioration in function and quality of life, mental and physical morbidity. The complaints of insomnia are present in 60–90% of patients with major depression, Complaints of disrupted sleep are very common in patients suffering from depression, (Wichniak, etal., 2017).
Questions you might ask the patient and rationale
The diagnosis and treatment of insomnia rely mainly on a thorough sleep history to address the precipitating factors as well as maladaptive behaviors resulting in poor sleep (Bollu & Kaur, 2019).
What is your sleep pattern including how many hours of sleep do you get at night prior to your husband’s demise and what it has been in the 10 months since his death? Does she perform certain rituals or do something special before she sleeps. This assesses if the insomnia started before or after the husband’s death. This provides a clue to insomnia that may be related to bereavement.
What time do you go to bed every night and what is your normal routine before going to bed? This is to check if the patient is doing something differently which has disrupted her normal routine and caused insomnia.
How often do you wake up to urinate at night? This question is asked to assess for nocturia due to diabetes that may lead to insomnia. Nocturia can prevent the patient from having a good night’s sleep. , changes in blood glucose levels at night causesto hypoglycemic and hyperglycemic episodes, nocturia and associated .
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
3. Source of InformationSource of Information
Informants – Patient,Informants – Patient,
Patient’s father &Patient’s father &
Patient’s cousinPatient’s cousin
CRF, Old prescriptionsCRF, Old prescriptions
investigation reportsinvestigation reports
Information is reliable & adequateInformation is reliable & adequate
4. PRESENTING COMPLAINTS
Sexual attraction towards children – 9 yrs
Concerns having small penis – 8-9 yrs
Low mood, interest in activities – 8 yrs
Headache – 8 yrs ( 2 yrs)
Decreased energy Remaining alone
Death wishes
6-7 months
5. HISTORY OF PRESENT ILLNESS
• Onset - Insidious
• Course - continuous
• Progress - Deteriorating
6.
7. TREATMENT HISTORY
DateDate DrugsDrugs DurationDuration ComplianceCompliance ResponseResponse SideSide
effecteffect
Dec 2007-Dec 2007-
DermatologiDermatologi
st,st,
AzamgarhAzamgarh
REASSURANCEREASSURANCE
T. Duloxetine 40mgT. Duloxetine 40mg BDBD
T. Alprazolam 0.25mgT. Alprazolam 0.25mg
+ propranolol 20mg+ propranolol 20mg
Cap. MultivitaminsCap. Multivitamins
? T.Camifto BD? T.Camifto BD
4 month4 month GoodGood GoodGood
(attributes(attributes
toto
reassuran-reassuran-
ce)ce)
NoNo
Oct -Nov 08Oct -Nov 08
AllahabadAllahabad
govt.hospitalgovt.hospital
T. B complexT. B complex
T. ClonazepamT. Clonazepam
0.25mg HS0.25mg HS
20 days20 days GoodGood NoNo NoNo
Dec 2008Dec 2008 T. Escitalopram 10T. Escitalopram 10
mgmg
T.Lorazepam 1 mgT.Lorazepam 1 mg
15 days15 days GoodGood NoNo NoNo
8. TREATMENT HISTORY Cont……..
Date Drugs Duration Compliance Response Side
effects
Dec 2008
Dermatologist,
Azamgarh
T .Fluoxetine 20mg BD
T.Alprazolam0.25mg+
T.Propranolol20mg
1 month Good No No
Feb. 2009
Physician
Azamgarh
T. Sertraline 50 mg HS
T. Ergotamine 1mg
+ Caffeine 100mg +
Belladona 10mg +
Paracetamol 250 mg SOS
T.Flunarazine 10 mg HS
T. Clonazepam 0.25mg HS
2 month Good Decreased
frequency
of
headache
No
May 2009 T. Propranolol HS
T.Sertraline 50mg OD
T. Clonazepam 1mg HS
1month Good No No
9. TREATMENT HISTORY Cont……..
DateDate DrugsDrugs DurationDuration ComplianceCompliance ResponseResponse SideSide
effecteffect
Sep. 2009,Sep. 2009,
Physician,Physician,
AzamgarhAzamgarh
T. Divalproate 500-T. Divalproate 500-
800mg OD800mg OD
T. Sertraline 50 mg HS
T. Meloxicam BD
Cap. Multivitamins
15 days15 days GoodGood NoNo NoNo
Oct. 2009,Oct. 2009,
Pvt.Pvt.
Psychiatrist,Psychiatrist,
AzamgarhAzamgarh
? T. Reximine? T. Reximine
TDSTDS
T.Hydroxyzine HST.Hydroxyzine HS
Cap.Cap. MMultivitamins
1 month1 month GoodGood NoNo NoNo
Nov. 2009,Nov. 2009,
Pvt.Pvt.
Psychiatrist,Psychiatrist,
AzamgarhAzamgarh
T. EscitalopramT. Escitalopram 55
mg/ daymg/ day
T. OlanzapineT. Olanzapine 2.5 mg2.5 mg
HSHS
T. AlprazolamT. Alprazolam 0.5mg0.5mg
BDBD
1 month1 month GoodGood NoNo NoNo
11. PAST HISTORY -Nil contributory
FAMILY HISTORY
• Born out of non consanguineous marriage. No contributory history
PERSONAL HISTORY
• FTNVD at home, no antenatal, natal or post natal complication.
• Normal developmental milestone.
• Congenial home atmosphere.
• Completed BSc in 2004.
• Worked with brother as insurance agent for 2 years.
• Currently studying BEd .
FORENSIC HISTORY
• Nil reported
PREMORBID TEMPERAMENT-Well adjusted
12. PHYSICAL EXAMINATIONPHYSICAL EXAMINATION
General Appearance-General Appearance-
Average body built .weight-67kgsAverage body built .weight-67kgs
pallor, cyanosis, clubbingpallor, cyanosis, clubbing -- NilNil
Icterus, oedema, neck veinIcterus, oedema, neck vein
No thyromegalyNo thyromegaly
Cardiovascular systemCardiovascular system
Pulse- 88/min, regular, good volume, no radio-radial andPulse- 88/min, regular, good volume, no radio-radial and
no radio-femoral delayno radio-femoral delay
B.P-126/84 mm of Hg, right brachial, supineB.P-126/84 mm of Hg, right brachial, supine
11stst
&2&2ndnd
heart sounds audibleheart sounds audible
no murmur.no murmur.
13. RESPIRATORY SYSTEMRESPIRATORY SYSTEM
Respiratory rate 19/min, abdomino thoracicRespiratory rate 19/min, abdomino thoracic
Trachea central normal symmetrical movementTrachea central normal symmetrical movement
B/l chest clear, no adventitious soundsB/l chest clear, no adventitious sounds
AbdomenAbdomen
Flat no distention.Flat no distention.
soft , nontender, no organomegalysoft , nontender, no organomegaly
BSBS ++
GenitalsGenitals
Penis flaccid state-5.5cm.(7-11cm)Penis flaccid state-5.5cm.(7-11cm)
Erect state-11.5cm(14-17cm)Erect state-11.5cm(14-17cm)
Scrotum-normal testisScrotum-normal testis
14. Central nervous systemCentral nervous system
Patient conscious, comprehension normal.Patient conscious, comprehension normal.
Speech and language normalSpeech and language normal
Cranial nerve examination within normal limitsCranial nerve examination within normal limits
Motor system & reflexes within normal limit.Motor system & reflexes within normal limit.
Sensory system intact.Sensory system intact.
Cortical functions intactCortical functions intact
Autonomic system within normal limitAutonomic system within normal limit
No signs of meningeal irritationNo signs of meningeal irritation
Cerebellar signs not presentCerebellar signs not present
Gait, spine within normal limitsGait, spine within normal limits
16. MENTAL STATUS EXAMINATIONMENTAL STATUS EXAMINATION
Kempt, tidy, in touch with the surrounding, lookingKempt, tidy, in touch with the surrounding, looking
good and appropriate to his age, average body built,good and appropriate to his age, average body built,
adequately dress, down gazing, poorly making eyeadequately dress, down gazing, poorly making eye
contactcontact
Cooperative attitude, rapport established.Cooperative attitude, rapport established.
Normal and appropriate motor behaviorNormal and appropriate motor behavior
Speech- soft tone , intensity, normal reaction time,Speech- soft tone , intensity, normal reaction time,
relevant, coherent, goal directed, normal productivityrelevant, coherent, goal directed, normal productivity
17. Cognitive functions- within normal limits.Cognitive functions- within normal limits.
Affect-depressed,Affect-depressed,
restricted range & normal reactivityrestricted range & normal reactivity
communicable appropriatecommunicable appropriate
Thought : stream-no abnormalityThought : stream-no abnormality
form - no abnormalityform - no abnormality
Possession -no abnormalityPossession -no abnormality
18. Thought content: Somatic concernsThought content: Somatic concerns
ideas of hopelessnessideas of hopelessness
ideas of helplessnessideas of helplessness
deathdeath wisheswishes
Perception: No abnormality elicitedPerception: No abnormality elicited
Judgment : impaired personalJudgment : impaired personal
insight :grade IVinsight :grade IV
20. DIAGNOSTIC FORMULATION
Index patient Mr. M.K.Y 25 yrs U/H/M, MSES rural background of
U.P, nil contributory past history, nil contributory family history well
adjusted premorbid temperament comes with history of feeling
attracted towards children 9 years with 3 incidents of sexual act with a
prepubertal child with history of concern about having small thin penis
for 8 years with low mood, lack of interest in activities for 8 years with
headache from 8 years increased from last 2 years with remaining to
self, decreased energy death wishes 5-7 months with GPE-WNL with
Mental Status Examination- Kempt tidy, co-operative with soft speech,
normal cognition. Depressed affect restricted range with somatic
concern, ideas of hopelessness, helplessness & death wishes with
impaired personal judgment and grade IV insight.
21. DIAGNOSIS
ICD-10: Hypochondriacal disorder(F- 45.2)
Paedophilia(F-65.4)
Dysthymia(F-34.1)
Moderate depressive episode with somatic
symptoms(F-32,11)
Tension type of headache(G44.2)
Probable Migraine without aura(G-43.83)
22. DSM-IV-TR
Axis I :300.7 Body dysmorphic disorder
302.2 Pedophilia, Sexually attracted to both,
Non exclusive type
300.4 Dysthymia
296.22Major depressive Disorder, single episode, moderate
Axis II :No Diagnosis
Axis III :Tension type headache
Probable Migraine without aura
Axis IV : No Diagnosis
Axis V : GAF-40(current)
23. PLAN OF MANAGEMENTPLAN OF MANAGEMENT
PharmacologicalPharmacological :-:-
1.1. SSRI to be continued as treatment of choice as it is helpful inSSRI to be continued as treatment of choice as it is helpful in
BDD, Pedophilia and DepressionBDD, Pedophilia and Depression
2.2. Topiramate to continue as prophylaxis of migraine headacheTopiramate to continue as prophylaxis of migraine headache
NonpharmacologicalNonpharmacological :-:-
1.1. Cognitive behaviour therapy is found to be effective .Cognitive behaviour therapy is found to be effective .
2.2. Psychoeducation to patient & his family.Psychoeducation to patient & his family.